Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.

Looking to nature for answers to complex questions can reveal new and unprecedented results that can even affect cells on ...